Drug Profile


Latest Information Update: 29 Jul 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Second State Medical Institute
  • Class Antihyperlipidaemics; Antiplatelets
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 29 Jul 1998 No-Development-Reported for Hyperlipidaemia in Uzbekistan (Unknown route)
  • 30 May 1995 A study of patients with ischaemic heart disease was added to the Hyperlipidaemia therapeutic trials section
  • 10 Nov 1994 Investigation in Hyperlipidaemia in Uzbekistan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top